Peer-reviewed studies show relative amputation risk reduced by over 70% in diabetic foot ulcer patients.

Within five years of amputation, half of amputees die.

**The Problem**
The U.S. embargo prevents introducing Cuban-origin medications into the United States for doctors and their patients, without specific licenses from the U.S. Department of the Treasury.

**The Solution**
The Administration can issue a general license to permit life-saving Cuban products to advance normally through the FDA process, disentangled from the larger debate on the US embargo on Cuba. A general license would permit marketing of Cuban medicines that clear FDA clinical trials.

**Cost to U.S. Health Care and Patients**
According to the American Diabetes Association, $1 of every $5 U.S. healthcare dollars is spent treating patients with diabetes.

Studies in peer-reviewed journals (International Wound Journal, Diabetes Care and MEDICC Review) show Heberprot-P has been proven effective for preventing diabetic foot ulcers, which account for $50 billion in annual direct medical costs.

**DIABETIC FOOT ULCERS:**
New Cuban Biotech Treatment Prevents Amputation

**HEBERPROT-P**

Currently available in 26 countries.

Not available in the United States.

**A WIDESPREAD DISEASE...**
29 million people in the United States suffer from diabetes

Roughly 75,000 of them will require amputation from diabetic foot ulcers

...ESPECIALLY AMONG MINORITIES

<table>
<thead>
<tr>
<th>% of population with diabetes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Native Americans &amp; Alaska Natives</td>
<td>16%</td>
</tr>
<tr>
<td>African Americans</td>
<td>15%</td>
</tr>
<tr>
<td>Hispanics</td>
<td>12%</td>
</tr>
<tr>
<td>Asian Americans &amp; Pacific Islanders</td>
<td>8%</td>
</tr>
<tr>
<td>Non-Hispanic Whites</td>
<td>7%</td>
</tr>
</tbody>
</table>

MEDICCC
Medical Education Cooperation with Cuba